Design Therapeutics (DSGN) Assets (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Assets data on file, last reported at $230.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 2.96% year-over-year to $230.4 million; the trailing twelve-month figure through Mar 2026 stood at $230.4 million (down 2.96% YoY), and the FY2025 full-year result was $226.2 million, down 10.27% from the prior year.
• Assets climbed to $230.4 million in Q1 2026, from $226.2 million in the prior quarter.
• In the past five years, Assets ranged from a high of $378.8 million in Q1 2022 to a low of $211.8 million in Q3 2025.
• A 5-year average of $285.8 million and a median of $278.8 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets declined 19.06% in 2025 and dropped 2.96% in 2026, its largest moves.
• Tracing DSGN's Assets over 5 years: stood at $341.1 million in 2022, then decreased by 15.09% to $289.6 million in 2023, then decreased by 12.96% to $252.1 million in 2024, then retreated by 10.27% to $226.2 million in 2025, then grew by 1.87% to $230.4 million in 2026.
• Business Quant data shows DSGN's Assets at $230.4 million in Q1 2026, $226.2 million in Q4 2025, and $211.8 million in Q3 2025.